Aptus Pharma Ltd: BSE Grants In-Principle Approval for Preferential Issue

Aptus Pharma Ltd has received in-principle approval from BSE Limited for a proposed preferential issue of equity shares. The approval, dated October 30, 2026, pertains to the issuance of 15,99,270 equity shares at a price not less than ₹280 per share to promoters and non-promoters. This follows shareholder approval at the Annual General Meeting held on September 14, 2026. BSE has advised the company to strengthen internal controls and obtain undertakings from allottees to prevent intra-day trading before allotment. The company must comply with all relevant SEBI regulations and ensure timely listing application post-allotment.